



1653

PATENTS

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: J. Henkin, *et al.*

Serial No.: 09/447,226

Filed: November 22, 1999

For: PEPTIDE ANTIANGIOGENIC
DRUGS

Case No.: 6356.US.P3

Group Art No.: 1653

Examiner: D. Lukton

Director of Patents and Trademarks
Washington, D.C. 20231

Certificate of Mailing (37 CFR 1.8 (a))

I hereby certify that this paper (along with any paper referred to as being attached or enclosed) is being deposited with the United States Postal Service on the date shown below with sufficient postage as first class mail in an envelope addressed to the:

Director of Patents and Trademarks
Washington, D.C. 20231, on;

Date of Deposit: May 8, 2002


Michele M. Bonke Date

RECEIVED

MAY 16 2002

TECH CENTER 1600/2900

TRANSMITTAL LETTER

Dear Sir:


Enclosed herewith for the patent application identified above entitled PEPTIDE ANTIANGIOGENIC DRUGS are the following:

1. Supplemental Amendment
2. Transmittal Letter, in duplicate
3. Return Receipt Postcard

The Commissioner is hereby authorized to charge any additional Filing Fees required under 37 CFR §1.16, as well as any patent application processing fees under 37 CFR §1.17 associated with this communication for which full payment had not been tendered, to Deposit Account No. 01-0025.

23492

23492

ABBOTT LABORATORIES
Telephone: (847) 937-3810
Facsimile: (847) 938-2623Respectfully submitted,
J. Henkin, *et al.*
B. Gregory Donner
Registration No. 34,580
Attorney for Applicants



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: J. Henkin, *et al.*

Serial No.: 09/447,226

Filed: November 22, 1999

For: PEPTIDE ANTIANGIOGENIC
DRUGS

Case No.: 6356.US.P3

Group Art No.: 1653

Examiner: D. Lukton

Certificate of Mailing (37 CFR 1.8 (a))

I hereby certify that this paper (along with any paper referred to as being attached or enclosed) is being deposited with the United States Postal Service on the date shown below with sufficient postage as first class mail in an envelope addressed to the:

Director of Patents and Trademarks
Washington, D.C. 20231, on:

Date of Deposit: May 8, 2002

Michele M. Bonke

Date

SUPPLEMENTAL AMENDMENT

RECEIVED

MAY 16 2002

TECH CENTER 1600/2900

Director of Patents and Trademarks
Washington, D.C. 20231

Dear Sir:

This communication is supplemental to the response mailed on March 14, 2002, which was written in response to the Restriction Requirement dated January 14, 2002.

Before examination on the merits, kindly enter this amendment and reconsider the subject application in view of the following remarks.

Text to be deleted is bracketed with bolded brackets to distinguish it from non-bolded, bracketed text which is not meant to be deleted.

Thirty (30) claims, including nineteen (19) independent claims are still pending in the subject application.

IN THE SPECIFICATION

On page 2, please replace the paragraph from line 12 to line 25 with the following paragraph:

In one aspect, the present invention provides a compound of formula:

B2